E-ISSN 2148-5607
Plasma transforming growth factor-β1 level in inflammatory bowel disease
(Turk J Gastroenterol 2009; 20: 165-170)
DOI: 10.4318/tjg.2009.0002
Effects of polymorphism in G2677T/A triallelic region of MDR1 gene in Turkish patients with inflammatory bowel disease
(Turk J Gastroenterol 2008; 19: 168-173)
Bone mineralization in children with inflammatory bowel disease: What is the role of zinc?
(Turk J Gastroenterol 2008; 19: 234-238)
The importance of peripheral immune cells in inflammatory bowel disease
(Turk J Gastroenterol 2007; 18: 82-88)
Infliximab treatment of pediatric refractory Crohn’s disease: A case report
(Turk J Gastroenterol 2006; 17: 133-136)
Epidemiology of inflammatory bowel disease
(Turk J Gastroenterol 1999; 10: 55-59)
Severe exudative ascites as an initial presentation of Crohn’s disease
(Turk J Gastroenterol 2005; 16: 171-173)
Prevalence of Celiac disease in Turkish children with type 1 Diabetes Mellitus and their non-diabetic first-degree relatives
(Turk J Gastroenterol 2010; 21: 34-38)
DOI: 10.4318/tjg.2010.0045
A case of Meckel’s diverticulitis treated on the assumption of Crohn’s disease
(Turk J Gastroenterol 2010; 21: 175-178)
DOI: 10.4318/tjg.2010.0079
Clinical importance of FXIII level in inflammatory bowel disease
(Turk J Gastroenterol 2001; 12: 45-48)
Serum eosinophilic cationic protein: A marker of eosinophilic infiltration in inflammatory bowel disease?
(Turk J Gastroenterol 2001; 12: 136-140)
Crohn’s colitis with extraintestinal manifestations: a case report
(Turk J Gastroenterol 2002; 13: 66-69)
The frequency of sacroileitis and ankylosing spondylitis in inflammatory bowel disease and HLA-B27 association
(Turk J Gastroenterol 2002; 13: 125-129)
Cyclosporin treatment of anal and perianal lesions associated with Crohn’s disease
(Turk J Gastroenterol 2003; 14: 121-127)
Pattern of gastrointestinal and psychosomatic symptoms across the menstrual cycle in women with inflammatory bowel disease
(Turk J Gastroenterol 2003; 14: 250-256)
Diagnostic value of serum procalcitonin in determining the activity of inflammatory bowel disease
(Turk J Gastroenterol 2009; 20: 9-12)
The efficacy of 5-ASA preparations in prevention of postoperative recurrence of Crohn’s disease (Retrospective assesstment)
(Turk J Gastroenterol 1999; 10: 276-279)
Clostridium difficile infection and inflammatory bowel disease
(Turk J Gastroenterol 2014; 25: 603-610)
DOI: 10.5152/tjg.2014.14054
Immunosuppressive therapy and the risk of hepatitis B reactivation: Consensus report
(Turk J Gastroenterol 2018; 29: 259-269)
DOI: 10.5152/tjg.2018.18263
Case Report
Limited form of wegener’s granulomatosis in a patient with Crohn’s disease. A case report
(Turk J Gastroenterol 2014; 25: 191-195)
DOI: 10.5152/tjg.2014.3846
Infliximab- and azathioprine-related severe neutropenia and thrombocytopenia in a case with Crohn’s disease
(Turk J Gastroenterol 2011; 22: 537-539)
DOI: 10.4318/tjg.2011.0409
Original Article
Different effect of smoking on genders in Crohn’s disease
(Turk J Gastroenterol 2015; 26: 133-139)
DOI: 10.5152/tjg.2015.5356
NOD2/CARD15 gene influences disease behaviour but not IBD susceptibility in a Moroccan population
(Turk J Gastroenterol 2014; 25: 122-128)
DOI: 10.5152/tjg.2014.3870
Characterization of de novo colonic stricture due to Crohn’s disease
(Turk J Gastroenterol 2014; 25: 129-132)
DOI: 10.5152/tjg.2014.7677
The effects of provocation by foods with raised IgG antibodies and additives on the course of Crohn’s disease: A pilot study
(Turk J Gastroenterol 2012; 23: 19-27)
DOI: 10.4318/tjg.2012.0332
Effects of enteral nutritional support on malnourished patients with inflammatory bowel disease by subjective global assessment
(Turk J Gastroenterol 2014; 25: 493-507)
DOI: 10.5152/tjg.2014.4955
Visual evoked potentials and pulse wave velocity in inflammatory bowel disease
(Turk J Gastroenterol 2015; 26: 15-19)
DOI: 10.5152/tjg.2015.4349
Assessment of presence and grade of activity in ileal Crohn’s disease
(Turk J Gastroenterol 2014; 25: 264-270)
DOI: 10.5152/tjg.2014.3862
No association between the functional cannabinoid receptor type 2 Q63R variants and inflammatory bowel disease in Turkish subjects
(Turk J Gastroenterol 2014; 25: 639-643)
DOI: 10.5152/tjg.2014.6568
Prevalence of QT interval prolongation in inflammatory bowel disease
(Turk J Gastroenterol 2016; 27: 136-142)
DOI: 10.5152/tjg.2015.150349
Incidence rate of anemia in inflammatory bowel diseases
(Turk J Gastroenterol 2016; 27: 143-148)
DOI: 10.5152/tjg.2016.16011
Endoscopic balloon dilation for stenotic lesions in Crohn’s disease
(Turk J Gastroenterol 2017; 28: 117-124)
DOI: 10.5152/tjg.2017.16598
Investigation of IL23R, JAK2, and STAT3 gene polymorphisms and gene–gene interactions in Crohn’s disease and ulcerative colitis in a Turkish population
(Turk J Gastroenterol 2016; 27: 525-536)
DOI: 10.5152/tjg.2016.16327
Letter to the Editor
What is the most accurate method for the assesment of small bowel in involvement in Crohn’s disease?
(Turk J Gastroenterol 2010; 21: 80-82)
DOI: 10.4318/tjg.2010.0060
Gastrointestinal Tract - Original Article
Immunoglobulin G4-related immune responses to common food antigens in patients with ulcerative colitis and Crohn’s disease
(Turk J Gastroenterol 2019; 30: 408-414)
DOI: 10.5152/tjg.2019.18466
Differential diagnosis of Crohn’s disease using antibodies to glycoprotein 2 and Saccharomyces cerevisiae
(Turk J Gastroenterol 2019; 30: 21-27)
DOI: 10.5152/tjg.2018.18135
Frequency and risk factors of surgical recurrence of Crohn’s disease after primary bowel resection
(Turk J Gastroenterol 2018; 29: 655-663)
DOI: 10.5152/tjg.2018.17774
Predictive parameters of early postoperative complications in Crohn’s disease: Single team experience
(Turk J Gastroenterol 2018; 29: 406-410)
DOI: 10.5152/tjg.2018.17687
Liver - Original Article
Reactivation rates in patients using biological agents, with resolved HBV infection or isolated anti-HBc IgG positivity
(Turk J Gastroenterol 2018; 29: 561-565)
DOI: 10.5152/tjg.2018.18032
Evaluation of rheumatologists’ awareness of hepatitis B reactivation before immunosuppressive treatment
(Turk J Gastroenterol 2019; 30: 25-25)
DOI: 10.5152/tjg.2019.14
Hepatitis b reactivation rate in patients using anti tnf theraphy: Evaluation of patients not received anti viral prophylaxis
(Turk J Gastroenterol 2019; 30: 38-38)
DOI: 10.5152/tjg.2019.24
Prospective and Randomized Comparison of Tenofovir and Entecavir in Hepatitis B Reactivation Prophylaxis in Patients Receiving Immunosuppressive Therapy
(Turk J Gastroenterol 2019; 30: 73-73)
DOI: 10.5152/tjg.2019.48
Clinical outcomes after cessation of potent antiviral treatment in chronic hepatitis B patients
(Turk J Gastroenterol 2019; 30: 81-82)
DOI: 10.5152/tjg.2019.54
Comparison of antivirals in prophylaxis of HBV reactivation in patients receiving immunsuppressive therapy
(Turk J Gastroenterol 2019; 30: 92-92)
DOI: 10.5152/tjg.2019.61
Key Words
Reviewer's Corner
Author’s Corner
AVES | Copyright © 2019 Turkish Society of Gastroenterology | Latest Update: 30.05.2019